Edition:
India

Vascular Biogenics Ltd (VBLT.OQ)

VBLT.OQ on NASDAQ Stock Exchange Global Market

6.70USD
15 Dec 2017
Change (% chg)

$-0.10 (-1.47%)
Prev Close
$6.80
Open
$6.85
Day's High
$6.85
Day's Low
$6.62
Volume
38,466
Avg. Vol
54,253
52-wk High
$9.05
52-wk Low
$3.95

Latest Key Developments (Source: Significant Developments)

VBL therapeutics Q3 loss per share $0.24
Tuesday, 14 Nov 2017 

Nov 14 (Reuters) - Vascular Biogenics Ltd :VBL Therapeutics announces third quarter 2017 financial results.Q3 loss per share $0.24.Q3 earnings per share view $-0.20 -- Thomson Reuters I/B/E/S.Vascular Biogenics Ltd - ‍ remain on-track to initiate a phase 3 study of vb-111 in ovarian cancer by year-end 2017​.Vascular Biogenics Ltd - ‍ also planning an exploratory clinical study in combination with a checkpoint inhibitor in lung cancer in q1 of 2018​.Vascular Biogenics - ‍expect cash, cash equivalents, short-term bank deposits to enable funding operating expenses and capex requirements through 2019​.  Full Article

VBL Therapeutics and Nanocarrier signs agreement for VB-111 in Japan
Monday, 6 Nov 2017 

Nov 6 (Reuters) - Nanocarrier Co Ltd <4571.T>:VBL Therapeutics and Nanocarrier Co Ltd sign exclusive agreement for VB-111 in Japan.Vascular Biogenics Ltd - ‍Nanocarrier receives exclusive rights to VB-111 in Japan, VBLT retains rights in rest of world​.Vascular - Pursuant to agreement, VBLT to supply nanocarrier with VB-111.Vascular - Nanocarrier will be responsible for all regulatory, other clinical activities necessary for commercialization of VB-111 in Japan.Vascular - VBLT receives up-front payment of $15 million & is entitled to receive greater than $100 million in development & commercial milestone payments​.Vascular Biogenics Ltd - ‍VBLT will also receive tiered royalties on net sales in high-teens​.Vascular Biogenics Ltd - ‍Other terms of agreement not disclosed​.  Full Article

Nanocarrier signs exclusive agreement with VBL Therapeutics for VB-111 in Japan
Monday, 6 Nov 2017 

Nov 6 (Reuters) - NanoCarrier Co Ltd <4571.T>:Says co signs an exclusive license agreement with VBL Therapeutics, for the development, commercialization, and supply of ofranergene obadenovec ("VB-111") in Japan.Under terms of the agreement, VBL Therapeutics will supply the co with VB-111, and the co will be responsible for all regulatory and other clinical activities necessary for commercialization in Japan.Says VBL Therapeutics will receive up-front payment of $15 million, development and commercial milestone payments and tiered royalties on net sales from the co.  Full Article

VBL THERAPEUTICS OPENS NEW GENE THERAPY MANUFACTURING PLANT, HEADQUARTERS
Monday, 23 Oct 2017 

Oct 23 (Reuters) - Vascular Biogenics Ltd ::VBL THERAPEUTICS CELEBRATES OPENING OF ITS NEW GENE THERAPY MANUFACTURING PLANT AND COMPANY HEADQUARTERS.PLANT IN MODIIN, ISRAEL WILL BE COMMERCIAL FACILITY FOR PRODUCTION OF OFRANERGENE OBADENOVEC (VB-111), IF APPROVED​.‍VBL EXPECTS THAT CURRENT CASH WILL FUND COMPANY'S OPERATING EXPENSES AND CAPITAL EXPENDITURE REQUIREMENTS INTO 2019​.  Full Article

VBL Therapeutics says VB-111 given orphan drug designation in Europe
Friday, 20 Oct 2017 

Oct 20 (Reuters) - Vascular Biogenics Ltd :VBL Therapeutics announces orphan drug designation for VB-111 in Europe.VBL Therapeutics - ‍European Medicines Agency designated ofranergene obadenovec as an "orphan medicinal product" for treatment of ovarian cancer​.  Full Article

VBL Therapeutics announces plans to establish new manufacturing facility
Thursday, 13 Oct 2016 

Vascular Biogenics Ltd : VBL Therapeutics announces plans to establish new manufacturing facility . Vascular Biogenics Ltd - near-term investment is not expected to materially impact VBL's cash position . Vascular Biogenics Ltd - projects that its current cash will suffice to support operations into 2019 . Vascular Biogenics Ltd - intends to operate and relocate to new site in second half of 2017 . Vascular Biogenics Ltd - engaged in a long-term lease contract of a new stand-alone facility in modiin, israel .Vascular Biogenics Ltd - new facility will also include company's headquarters, discovery research and clinical development.  Full Article

Thai Lee Family Trust reports 21.6 pct stake in Vascular Biogenics
Thursday, 25 Aug 2016 

Vascular Biogenics Ltd :Thai Lee Family Trust reports 21.6 percent stake in vascular biogenics ltd as of january 19 - Sec filing.  Full Article

VBL Therapeutics posts Q2 loss per share of $0.14
Monday, 15 Aug 2016 

Vascular Biogenics Ltd : Q2 loss per share $0.14 . VBL Therapeutics announces second quarter 2016 financial results and provides business update .Q2 earnings per share view $-0.23 -- Thomson Reuters I/B/E/S.  Full Article

VBL Therapeutics posts Q1 loss per share of $0.21
Friday, 13 May 2016 

Vascular Biogenics Ltd : Trial for VB-111 is recruiting on schedule; interim data is expected in H1 2017 . Full trial results for VB-111 expected late in 2017 or early 2018 . VBL Therapeutics announces first quarter 2016 financial results and provides business update . Q1 loss per share $0.21 .Q1 earnings per share view $-0.21 -- Thomson Reuters I/B/E/S.  Full Article